Expert Illustrations & Commentaries Live: The Future of JAK/TYK2 Inhibition in the Treatment of Psoriasis

Target Audience
This educational activity is directed toward the dermatologists, nurse practitioners, and physician assistants who treat patients with dermatologic conditions.

Program Overview
This online, on-demand virtual symposium brings together renowned experts in dermatology to discuss newer treatments for patients with psoriasis. Psoriasis has no clearly defined cause or cure, but it does have a significant impact on quality of life. It is now recognized as a systemic disease associated with psoriatic arthritis and other serious comorbidities. The critical pathogenic pathway in psoriasis is considered to be the interleukin (IL)-23/IL-17 axis. This pathway uses the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway to transduce intracellular signals. Although small molecules that block the JAK/STAT pathway and reduce inflammation have been developed, their relative nonspecific nature and toxicity have hindered their use in patients with psoriasis. Current research is focused on tyrosine kinase 2 (TYK2) inhibitors, which have more favorable efficacy and safety profiles.

In this CME activity, a panel of experts discusses treatment options for patients with psoriasis, focusing on newer TYK2 inhibitors. The program includes a short, animated video that illustrates the mechanism of action of newer therapeutic agents in psoriasis.

This educational activity is an archive of the live virtual symposium, held on January 25, 2022.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Describe the etiology, pathophysiology, and important considerations in the diagnosis of psoriasis.
Evaluate the latest data on the efficacy, safety, dosing, and administration of novel TYK2 inhibitors for patients with psoriasis.
Integrate targeted TYK2 inhibitors into the treatment of psoriasis.